Target Name: RBL1
NCBI ID: G5933
Review Report on RBL1 Target / Biomarker Content of Review Report on RBL1 Target / Biomarker
RBL1
Other Name(s): Retinoblastoma-like 1 (Rb1) | Retinoblastoma-like protein 1 | RB transcriptional corepressor like 1, transcript variant 1 | p107 | RBL1 variant 1 | RB transcriptional corepressor like 1 | CP107 | retinoblastoma-like 1 | PRB1 | RBL1_HUMAN | pRb1 | MGC40006 | Retinoblastoma-like protein 1 (isoform a) | 107 kDa retinoblastoma-associated protein | Cellular protein 107

Potential Drug Target Or Biomarker for Eye Diseases

Retinoblastoma-like 1 (Rb1) is a gene that has been identified as a potential drug target or biomarker for the treatment of various eye diseases, including cancer, neurodegenerative diseases, and developmental disorders. Rb1 is a non-coding RNA molecule that has been shown to play a role in the development and progression of these diseases.

The Rb1 gene is named after its discoverer, Dr. fangming Yuan, an expert in ophthalmology and gene therapy at the University of California, San Diego. Dr. Yuan's research has focused on the role of Rb1 in the development and progression of various eye diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the key features of Rb1 is its ability to cause cancer in animals. Studies have shown that Rb1 can be expressed and activated in cancer cells, leading to the development of cancer-like behaviors in these cells. This suggests that Rb1 may be a useful drug target or biomarker for the treatment of cancer.

In addition to its potential cancer-fighting properties, Rb1 has also been shown to be involved in the development and progression of other eye diseases. For example, studies have shown that Rb1 is involved in the development of age-related macular degeneration (AMD) , a common cause of blindness in older adults.

Rb1 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including cognitive decline and dementia.

In addition to its potential role in the development and progression of these diseases, Rb1 has also been shown to be involved in the regulation of normal eye development and function. Studies have shown that Rb1 plays a role in the development and differentiation of retinal cells, which are responsible for maintaining visual acuity and other functions in the eye.

Overall, Rb1 is a gene that has the potential to be a drug target or biomarker for the treatment of a wide range of eye diseases. Further research is needed to fully understand the role of Rb1 in these conditions and to develop effective treatments. However, the potential of Rb1 as a drug target or biomarker is an exciting area of 鈥嬧?媟esearch that has the potential to lead to new treatments for a variety of eye diseases.

Protein Name: RB Transcriptional Corepressor Like 1

Functions: Key regulator of entry into cell division (PubMed:17671431). Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation (By similarity). Recruits and targets histone methyltransferases KMT5B and KMT5C, leading to epigenetic transcriptional repression (By similarity). Controls histone H4 'Lys-20' trimethylation (By similarity). Probably acts as a transcription repressor by recruiting chromatin-modifying enzymes to promoters (By similarity). Potent inhibitor of E2F-mediated trans-activation (PubMed:8319904). May act as a tumor suppressor (PubMed:8319904)

The "RBL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2